

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Heimer G, Gregory A, Hogarth P, et al. *MECR*-Related Neurologic Disorder. 2019 May 9. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews<sup>®</sup> [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/

# **MECR-Related Neurologic Disorder**



Synonym: Mitochondrial Enoyl CoA Reductase Protein-Associated Neurodegeneration (MEPAN)

Gali Heimer, MD, PhD,<sup>1,2</sup> Allison Gregory, MS,<sup>3</sup> Penelope Hogarth, MD,<sup>3</sup> Susan Hayflick, MD,<sup>4</sup> and Bruria Ben Zeev, MD, Prof<sup>5</sup> Created: May 9, 2019.

# Summary

# **Clinical characteristics**

*MECR*-related neurologic disorder is characterized by a progressive childhood-onset movement disorder and optic atrophy; intellect is often – but not always – preserved. The movement disorder typically presents between ages one and 6.5 years and is mainly dystonia that can be accompanied by chorea and/or ataxia. Over time some affected individuals require assistive devices for mobility. Speech fluency and intelligibility are progressively impaired due to dysarthria. Optic atrophy typically develops between ages four and 12 years and manifests as reduced visual acuity, which can include functional blindness (also known as legal blindness) in adulthood. Because only 13 affected individuals are known to the authors, and because nearly half of them were diagnosed retrospectively as adults, the natural history of disease progression and other aspects of the phenotype have not yet been completely defined.

# **Diagnosis/testing**

The diagnosis of *MECR*-related neurologic disorder is established in a proband with a childhood-onset movement disorder and biallelic (compound heterozygous or homozygous) pathogenic variants in *MECR* identified by molecular genetic testing.

#### Management

*Treatment of manifestations:* Visual aids for decreased visual acuity due to optic atrophy; occupational therapy and physical therapy to maintain range of movement and special aids (e.g., braces, walkers, wheelchairs) to

**Author Affiliations:** 1 Pediatric Neurology Unit, Safra Children's Hospital; Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel HaShomer, Israel; Email: galih.md@gmail.com. 2 The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Email: galih.md@gmail.com. 3 Molecular and Medical Genetics, Oregon Health & Science University Portland, Oregon; Email: gregorya@ohsu.edu; Email: hogarthp@ohsu.edu. 4 Molecular and Medical Genetics, Pediatrics and Neurology, Oregon Health & Science University Portland, Oregon; Email: hogarthp@ohsu.edu. 5 Pediatric Neurology Unit, Safra Children's Hospital, Sheba Medical Center, Tel HaShomer, Israel, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Email: bruria.benzeev@sheba.health.gov.il.

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

maintain/improve mobility; speech therapy for dysarthria and augmentative communication if needed. Medications that may relieve dystonia include anticholinergic agents, baclofen, and benzodiazepines.

*Surveillance:* The following yearly examinations are warranted: ophthalmologic (need for additional visual aids), neurologic (need for medications to relieve dystonia), speech therapy (need for augmentative communication), cognitive evaluation, and feeding evaluation (assess risk of aspiration).

*Agents/circumstances to avoid:* Stress and febrile illness as much as possible as these are presumed to exacerbate disease progression. Discuss anesthetic risks with a patient's medical team prior to surgical procedures.

### **Genetic counseling**

*MECR*-related neurologic disorder is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the *MECR* pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic diagnosis are possible.

# Diagnosis

To date no formal diagnostic criteria have been published for MECR-related neurologic disorder.

# **Suggestive Findings**

*MECR*-related neurologic disorder **should be suspected** in individuals with the following clinical findings, neuroimaging findings, and ethnicity.

#### **Clinical findings**

- Childhood-onset dystonia, chorea, and other movement disorders: ages 1-6.5 years
- Childhood-onset optic atrophy: typically ages 4-12 years. Note that optic atrophy is not necessary to consider the diagnosis of *MECR*-related neurologic disorder in a young child as it may appear several years after the onset of the movement disorder.

**Neuroimaging findings.** On MRI, bilateral hyperintense T<sub>2</sub>-weighted signal in one or more structures of the basal ganglia (i.e., caudate, putamen, or pallidum) evident at time of onset of dystonia (Figure 1)

**Ethnicity.** Ashkenazi Jewish heritage. Note that while *MECR*-related neurologic disorder is more frequent in Ashkenazi Jews, it also occurs in persons of other ethnicities.

# **Establishing the Diagnosis**

The diagnosis of *MECR*-related neurologic disorder **is established** in a proband with Suggestive Findings and biallelic (compound heterozygous or homozygous) pathogenic (or likely pathogenic) variants in *MECR* by molecular genetic testing (Table 1).

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of biallelic *MECR* variants of uncertain significance (or of one known *MECR* pathogenic variant and one *MECR* variant of uncertain significance) does not establish or rule out the diagnosis.



**Figure 1.** Magnetic resonance imaging of individuals with *MECR*-related neurologic disorder showing hyperintense T<sub>2</sub>-weighted and FLAIR signals within the basal ganglia

A. T<sub>2</sub>-weighted axial section demonstrating hyperintense pallidal signal (arrow) (Family G, Patient II:1) [Author, unpublished observation]

B. T<sub>2</sub>-weighted axial section demonstrating hyperintense signal in both pallidum and putamen (arrows) (Family G, Patient II:6) [Author, unpublished observation]

C. Flair axial section demonstrating hyperintense signal in both putamen and caudate (arrows) (Family C, Patient II:8) [Heimer et al 2016]

Molecular genetic testing approaches can include a combination of **gene-targeted testing** (single-gene testing or a multigene panel) and **comprehensive genomic testing** depending on the phenotype.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of *MECR*-related neurologic disorder is distinctive, children with findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with a phenotype indistinguishable from other childhood-onset dystonias with bilateral symmetric basal ganglia signal intensity changes are more likely to be diagnosed using genomic testing (see Option 2).

#### **Option 1**

When the phenotypic and imaging findings suggest the diagnosis of *MECR*-related neurologic disorder, molecular genetic testing approaches can include **single-gene testing** or use of a **multigene panel**.

- **Single-gene testing.** Sequence analysis of *MECR* is performed first. If only one pathogenic variant is found, gene-targeted deletion/duplication analysis could be considered; however, to date no exon or whole-gene deletions have been reported.
- A dystonia multigene panel that includes *MECR* and other genes of interest (see Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while

limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Of note, given the novelty and rarity of *MECR*-related neurologic disorder, many panels for dystonia may not yet include this gene. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

#### **Option 2**

When the phenotype is indistinguishable from many other disorders of childhood-onset dystonia, **comprehensive genomic testing** (which does not require the clinician to determine which gene[s] are likely involved) is the best option. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

If exome sequencing is not diagnostic, **exome array** (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis. Note: To date such variants have not been identified as a cause of *MECR*-related neurologic disorder.

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1 1	Molecular	Conotic	Tecting	I lead in	MECP Related	Neurologic	Disordar
Table 1.1	violeculai	Genetic	resting	Oseu III	MILCA-Related	neuroiogie	Disoluci

Gene <sup>1</sup>	Method	Proportion of Probands with Pathogenic Variants <sup>2</sup> Detectable by Method
	Sequence analysis <sup>3</sup>	8/8 4
MECR	Gene-targeted deletion/duplication analysis <sup>5</sup>	Unknown <sup>6</sup>

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on allelic variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4. n = 5 [Heimer et al 2016]; n = 2 (families referred to the authors after the publication of Heimer et al 2016); n = 1 [Author, personal communication]

5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

6. No data on detection rate of gene-targeted deletion/duplication analysis are available.

# **Clinical Characteristics**

## **Clinical Description**

To date, the authors know of 13 individuals with *MECR*-related neurologic disorder: seven (5 probands and 2 family members) described by Heimer et al [2016], and six ascertained more recently by the authors (1 individual and 2 sets of sibs). The common clinical phenotype in these 13 individuals is characterized by childhood-onset movement disorder followed by optic atrophy, and often – but not always – preserved intellect. Similar to other metabolic disorders, symptoms may fluctuate temporally with febrile illnesses. In one instance, the young child never fully regained motor skills lost after fever. Because of the limited number of affected individuals reported to date, and because nearly half of them were diagnosed retrospectively as adults, the natural history of progression of the known features of the disorder as well as other possible aspects of the phenotype have not yet been completely defined.

The motor disability and dysarthria progress with time. Severity may vary between affected individuals, even within the same family. Heimer et al [2016] describe a male age 46 years (Family C, Patient II:2) with unintelligible speech and contractures who was confined to a wheelchair and totally dependent for all activities of daily living, whereas his brother age 28 years (Patient II:8) walked independently despite limb dystonia and had slightly slurred dysarthric – but intelligible – speech.

In a different family of two affected brothers (ages 5 and 6 years), one had progressive dystonia, spasticity, and ataxia whereas the other had predominantly hypotonia and neck muscle weakness; neither has walked independently [Family F; Author, unpublished observations].

In a third family with three affected sisters, the oldest (currently age 15 years) started walking at about age two years, then exhibited pronounced chorea from age 5.5 years and dystonia from age 12 years. The youngest (currently age 4 years) exhibited arm dystonia at age one year, walked independently at age 22 months, and currently manifests dystonia of all limbs and facial chorea. In contrast, the middle sister (currently age 5.5 years) started walking at age 12 months; neurologic examination revealed minimal dystonia of the left leg of which the parents had previously been unaware [Family G; Author, unpublished observations].

**Neurologic manifestations.** The presenting manifestation is an involuntary movement disorder, mainly dystonia that can be accompanied by chorea and/or ataxia.

Onset of the movement disorder is during early childhood (12 months–6.5 years). However, a history of hypotonia, increased laxity, and delayed motor development from the first year of life is possible.

The motor disability gradually progresses; over time, some affected individuals require a walker or wheelchair for ambulation. Some with earlier onset and more rapid progression may never walk independently.

Speech fluency and intelligibility are progressively impaired due to dysarthria. In some cases (e.g., the three sisters in Family G) articulation may be impaired at onset of speech, whereas in other children (e.g., the two brothers in Family F) speech may never develop despite relative preservation of receptive language.

Cognition was unaffected or relatively spared in five of the seven reported by Heimer et al [2016] (Family E). Of two brothers with impaired cognition, linguistic skills and executive function deteriorated to an extremely low range at age nine years in one (Patient II:1), whereas the other (Patient II:3) was reported to have low average verbal comprehension with extremely low function on the other WISC IV indices.

Although the oldest of the three sisters in Family G was suspected of having polyneuropathy (areflexia and decreased sensation noted around age two years), these findings were not evident on more recent examination. Furthermore, conflicting results of two nerve conduction velocity (NCV) tests several years apart cast doubt on whether these findings resulted from polyneuropathy or were other manifestations of *MECR*-related neurologic disorder.

To date, seizures and encephalopathy have not been reported.

**Ocular manifestations.** Optic atrophy develops within seven years of the onset of dystonia (i.e., between ages 4 and 12 years). It manifests as reduced visual acuity, which can include functional blindness in adulthood in some individuals.

Abnormal eye movements (nystagmus or roving eye movements) can also be seen.

Life expectancy. All currently known affected individuals are alive; two are in their fifth decade.

**Laboratory tests.** No consistent biomarker was found. Of note, elevated urinary 3 OH-isovaleric acid was found in one individual and 3 methyl glutaconic acid in another.

## **Genotype-Phenotype Correlations**

No clear genotype-phenotype correlations have been observed. Of the 13 currently known affected individuals, 12 are compound heterozygotes with various combinations of a missense variant and nonsense variant, and one is a homozygote for a missense variant [Heimer et al 2016 and personal communication]. These findings suggest that the combination of two nonsense variants could either be incompatible with life or give rise to a more severe phenotype.

#### Prevalence

To the authors' knowledge, only 13 individuals from eight families have been diagnosed with *MECR*-related neurologic disorder to date. Five of the eight families were of Ashkenazi Jewish origin, suggesting possible increased prevalence in this population [Heimer et al 2016 and personal communication].

Unpublished results based on the Inflammatory Bowel Disease Exomes Browser containing more than 5,500 exomes of Ashkenazi Jewish individuals revealed an increased frequency of two pathogenic variants among the Ashkenazi Jewish population:

- c.695G>A missense variant in 18/5,598; variant frequency of 1:311
- c.830+2dupT splice site variant in 41/5,576; variant frequency of 1:136

# **Genetically Related (Allelic) Disorders**

No phenotypes other than those discussed in this *GeneReview* are known to be associated with pathogenic variants in *MECR*.

# **Differential Diagnosis**

The differential diagnosis of *MECR*-related neurologic disorder includes disorders that combine the clinical features of childhood-onset movement disorder (mainly dystonia [see Hereditary Dystonia Overview] but also ataxia and chorea) and the MRI findings of signal abnormality in the basal ganglia present when the movement disorder appears.

**Table 2.** Disorders with Dystonia and MRI Signal Abnormality in the Basal Ganglia to Consider in the Differential Diagnosis of*MECR*-Related Neurologic Disorder

	Gene(s)	MOI	Clinical Features of Differential Disorder		
Differential Disorder			Overlapping w/ <i>MECR</i> -related neurologic disorder <sup>1</sup>	Distinguishing from <i>MECR</i> -related neurologic disorder	
Leigh syndrome (See Nuclear Gene- Encoded Leigh Syndrome Overview & Mitochondrial DNA- Associated Leigh Syndrome and NARP.)	See footnote 2.	AR, XL, Mit	<ul> <li>Optic atrophy may develop.</li> <li>Symptoms may worsen following febrile illness.</li> </ul>	<ul> <li>Typically seen:</li> <li>Seizures, encephalopathy, cognitive regression <ul> <li>↑ blood/CNS lactate</li> </ul> </li> <li>May be seen on MRI: <ul> <li>Signal abnormality in brain stem in addition to basal ganglia lesions</li> </ul> </li> </ul>	
Leber hereditary optic neuropathy	See footnote 3.	Mit	Optic atrophy is the main manifestation.	Onset usually after 3rd decade (although childhood onset has been reported)	

Table 2. continued from previous page.

		Clinical Features of Differential Disord		es of Differential Disorder
Differential Disorder	Gene(s)	MOI	Overlapping w/ $MECR$ -related neurologic disorder $^1$	Distinguishing from <i>MECR</i> -related neurologic disorder
Glutaric aciduria type 1 (OMIM 231670)	GCDH	AR	<ul> <li>Cognition may be preserved.</li> <li>Symptoms may worsen following febrile illness.</li> </ul>	<ul> <li>Typically seen:</li> <li>Macrocephaly &amp; widening of Sylvian fissures on MRI</li> <li>Episodes of acute encephalopathy w/dystonic crises</li> <li>↑ urine glutaric acid &amp; 3-OH- glutaric acid</li> </ul>
D-2-hydroxyglutaric aciduria (OMIM 609186)	D2HGDH	AR	Symptoms may worsen following febrile illness.	<ul> <li>Typically seen:</li> <li>Seizures, cardiomyopathy, cognitive regression</li> <li>↑ urine D-2-hydroxyglutaric acid</li> <li>May be seen:</li> <li>Subependymal cysts on MRI</li> <li>↑ blood/CNS lactate</li> </ul>
Biotin-thiamine- responsive basal ganglia disease	SLC19A3	AR	Dysarthria & eye mvmt abnormality are common.	<ul> <li>Typically seen:</li> <li>Encephalopathy</li> <li>Good response to high doses of biotin &amp; thiamine</li> <li>May be seen:</li> <li>Signal abnormality in the brain stem on MRI</li> </ul>
Huntington disease	HTT <sup>4</sup>	AD	Ataxia & chorea may also be present.	<ul> <li>Characteristic MRI feature: caudate head atrophy</li> <li>Parkinsonism common in juvenile form</li> </ul>
Chorea-acanthocytosis	VPS13A	AR	Dysarthria is common.	<ul> <li>Typically seen:</li> <li>Onset after 3rd decade (although childhood onset has been reported)</li> <li>Cognitive &amp; behavioral changes</li> <li>Caudate atrophy on MRI (characteristic feature)</li> <li>↑ creatine kinase &amp; acanthocytes</li> <li>Seizures (in almost half of affected persons)</li> </ul>
DRPLA <sup>5</sup>	ATNI	AD	Ataxia & chorea may also be present.	<ul> <li>Typically seen:</li> <li>Myoclonic epilepsy, behavioral changes, dementia</li> <li>Atrophic changes in cerebellum &amp; brain stem on MRI</li> </ul>

#### Table 2. continued from previous page.

	Gene(s)	MOI	Clinical Features of Differential Disorder		
Differential Disorder			Overlapping w/ $MECR$ -related neurologic disorder $^1$	Distinguishing from <i>MECR</i> -related neurologic disorder	
Wilson disease	ATP7B	AR	Chorea & dysarthria are common.	<ul> <li>Typically seen:</li> <li>Tremor, parkinsonism, behavioral changes</li> <li>Liver disease</li> <li>Kayser-Fleischer ring</li> <li>May be seen:</li> <li>Low serum ceruloplasmin &amp; high urinary copper</li> </ul>	
NBIA 6	See footnote 7.	AR, AD, XL	<ul> <li>Dysarthria is common.</li> <li>Optic atrophy may be present.</li> <li>Hyperintense T<sub>2</sub>-weighted signal may be observed in basal ganglia on brain MRI.</li> </ul>	<ul> <li>Typically seen:</li> <li>Parkinsonism &amp; neuropsychiatric abnormalities</li> <li>Brain iron accumulations &amp; (in some cases) accompanying cerebral &amp; cerebellar atrophy on MRI</li> </ul>	

AD = autosomal dominant; AR = autosomal recessive; Mit = mitochondrial; MOI = mode of inheritance; XL = X-linked

1. In addition to dystonia and MRI findings of signal abnormality in the basal ganglia

2. Leigh syndrome, a heterogeneous group of disorders, is associated with pathogenic variants in more than 70 genes (nuclear and mitochondrial).

3. Pathogenic variants in *MT-ND1*, *MT-ND4*, and *MT-ND6* account for >90% of cases; pathogenic variants in other mitochondrial genes are also possible.

4. Huntington disease is caused by an expansion of 36 or more CAG trinucleotide repeats in HTT.

5. DRPLA = dentatorubral-pallidoluysian atrophy

*6*. NBIA = neurodegeneration with brain iron accumulation

7. NBIA is a heterogeneous group of disorders associated with pathogenic variants in at least ten genes (see Neurodegeneration with Brain Iron Accumulation Disorders Overview).

## Management

#### **Evaluations Following Initial Diagnosis**

To establish the extent of disease and needs in an individual diagnosed with *MECR*-related neurologic disorder, the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

System/Concern	Evaluation	Comment
Eyes	Ophthalmologic eval	To assess for optic atrophy & visual acuity
Gastrointestinal/ Feeding	Gastroenterology / nutrition / feeding team eval	<ul> <li>Incl eval of aspiration risk &amp; nutritional status</li> <li>Consider eval for gastric tube placement in patients w/ dysphagia &amp;/or aspiration risk.</li> </ul>
Musculoskeletal	OT & PT assessments	To assess effect of mvmt disorder on activities of daily living

Table 3. Recommended Evaluations Following Initial Diagnosis

*Table 3. continued from previous page.* 

System/Concern	Evaluation	Comment
Neurologic	Brain MRI	<ul> <li>Medication management for dystonia</li> <li>Rehab w/therapies &amp; equipment needs assessment for dystonia, chorea, &amp;/or ataxia</li> </ul>
Development	Developmental assessment	<ul> <li>Incl eval of motor, speech/language, general cognitive, &amp; vocational skills</li> <li>Speech therapy &amp; augmentative communication consultation for dysarthria</li> </ul>
Neuropsychological	Assessment of cognitive function	
Miscellaneous/ Other	Consultation w/clinical geneticist &/or genetic counselor	Incl genetic counseling

OT = occupational therapy; PT = physical therapy

## **Treatment of Manifestations**

The following are appropriate:

- Visual aids can be used in cases of decreased visual acuity due to optic atrophy.
- Physiotherapy can be used to maintain range of movement.
- Occupational therapy can be used as appropriate to develop and maintain skills related to activities of daily living, which will vary across the life span.
- Special aids such as braces, walkers, and wheelchairs can maintain/improve mobility.
- Speech therapy, if speech dysarthria is present, and assessment for augmentative communication devices
- Medications that may relieve dystonia, such as anticholinergic agents, baclofen, and benzodiazepines, can be considered.
  - Anticholinergic agents act peripherally on the neuromuscular junction, but can have a variety of adverse central nervous system (CNS) effects.
  - Baclofen, which works on GABA<sub>B</sub> receptors and functions as a CNS depressant and skeletal muscle relaxant, can be administered either through an intrathecal pump or systemically (enterally).
  - Benzodiazepines, which are GABA<sub>A</sub> agonists, can reduce muscle tone and alleviate the dystonia; however, they also cause sedation.
- Deep brain stimulation (DBS): While some patients with severe dystonia are treated with DBS, experience with *MECR*-related neurologic disorder is limited. To date, there are no reports of individuals with this disorder treated with DBS. Moreover, due to the existence of basal ganglia lesions, DBS may not be suitable for many persons with *MECR*-related neurologic disorder.
- Of the three sisters (Family G; Author, unpublished observations), two are treated for ADHD: one with Vyvanse<sup>®</sup> (lisdexamfetamine dimesylate), which seems to also improve her dystonia and dysarthria; the other with Adderall, which seems to improve her dystonia and balance.

#### **Surveillance**

The following are recommended:

- Yearly eye examination to determine need for additional visual aids
- Yearly neurologic assessment to determine need for additional interventions, including speech therapy

#### **Agents/Circumstances to Avoid**

Disease progression is presumed to be exacerbated by stress or febrile illness; therefore, prevention of these – to the extent possible – is recommended.

One patient reported onset of significant new, long-term motor symptoms following extended anesthesia with propofol. As with other mitochondrial disorders, anesthetic considerations should be discussed with a patient's medical team prior to any surgical procedure [Niezgoda & Morgan 2013].

In one of the sisters (Family G), a test dose of dopamine worsened her chorea significantly.

### **Evaluation of Relatives at Risk**

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

### **Therapies Under Investigation**

The pathomechanism of *MECR*-related neurologic disorder suggests the possible therapeutic effect of supplementation with lipoic acid (LA) and octanoic acid (C8). One individual showed remarkable improvement after receiving LA and a nutritional supplement high in C8 within three months of symptom onset [Heimer et al 2016]. The authors are currently offering their patients treatment with a Mito Cocktail of coenzyme Q10, riboflavin, thiamine, and alpha lipoic acid with the addition of octanoic acid, vitamin E, and vitamin C (see also Author Notes). Of note, the efficacy of this regimen for treatment of *MECR*-related neurologic disorder has yet to be proven in an evidence-based manner.

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

# **Genetic Counseling**

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

## Mode of Inheritance

MECR-related neurologic disorder is inherited in an autosomal recessive manner.

### **Risk to Family Members**

#### Parents of a proband

- The parents of an affected child are obligate heterozygotes (i.e., carriers of one MECR pathogenic variant).
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

#### Sibs of a proband

- At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

**Offspring of a proband.** Unless an affected individual's reproductive partner also has *MECR*-related neurologic disorder or is a carrier, offspring will be obligate heterozygotes (carriers) for a pathogenic variant in *MECR*.

**Other family members.** Each sib of the proband's parents is at a 50% risk of being a carrier of an *MECR* pathogenic variant.

## **Carrier Detection**

Carrier testing for at-risk relatives requires prior identification of the MECR pathogenic variants in the family.

# **Related Genetic Counseling Issues**

#### Family planning

- The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

# Prenatal Testing and Preimplantation Genetic Testing

Once the *MECR* pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

# Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

 United Mitochondrial Disease Foundation Phone: 888-317-UMDF (8633)
 Email: info@umdf.org www.umdf.org

# **Molecular Genetics**

*Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information.* —ED.

Gene	Chromosome Locus	Protein	HGMD	ClinVar
MECR	1p35.3	Enoyl-[acyl-carrier-protein] reductase, mitochondrial	MECR	MECR

Table A. MECR-Related Neurologic Disorder: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

 Table B. OMIM Entries for MECR-Related Neurologic Disorder (View All in OMIM)

608205	MITOCHONDRIAL TRANS-2-ENOYL-CoA REDUCTASE; MECR
617282	DYSTONIA, CHILDHOOD-ONSET, WITH OPTIC ATROPHY AND BASAL GANGLIA ABNORMALITIES; DYTOABG

**Gene structure.** *MECR* (NM\_016011.4) comprises ten exons and a total of 2,539 bp. Multiple transcript variants have been reported. (For a detailed summary of gene, transcript, and protein information, see Table A, **Gene**.)

**Pathogenic variants.** To date, six pathogenic variants have been described: three missense, two nonsense, and one splice site [Heimer et al 2016]; see Table A, **Databases**. The frequency of two pathogenic variants is increased in Ashkenazi Jewish populations (see Prevalence; Table 4).

Table 4. MECR Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.695G>A <sup>1</sup>	p.Gly232Glu	NM_016011.4 NP_057095.4
c.830+2dupT <sup>1</sup>		NM_016011.4

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

*GeneReviews* follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of nomenclature.

1. See Prevalence.

**Normal gene product.** *MECR* encodes mitochondrial trans-2-enoyl-coenzyme A-reductase (MECR); the transcript NM\_016011.4 encodes a 373-amino acid protein (NP\_057095.4) with four main domains: mitochondrial transit peptide, NADPH cofactor-binding domain, and two catalytic domains. MECR catalyzes the last step of human mitochondrial fatty acid synthesis (mtFAS), turning trans-2-enoyl-ACP into acyl-ACP. MECR also serves as the precursor for lipoic acid synthesis, which functions as a cofactor for key enzymes of the respiratory chain [Hiltunen et al 2009].

**Abnormal gene product.** Decreased MECR activity reduces production of octanoyl-ACP (which regulates mitochondrial RNA processing and translation) and reduces respiratory complex assembly [Kursu et al 2013].

# **Chapter Notes**

### **Author Notes**

Dr Gali Heimer is a Senior Pediatric Neurologist and Director of the Angelman Clinic in the Pediatric Neurology Unit of the Edmond and Lily Safra Children's Hospital, and a member of the Talpiot Medical Leadership Program at the Sheba Medical Center.

Her clinical work and research focuses on neurogenetics: diagnosing known and novel genetic causes of rare neurologic diseases of childhood with emphasis on unraveling their pathomechanism and searching for therapeutic strategies.

The authors plan to test the effect of LA/C8 on cell lines from individuals with *MECR*-related neurologic disorder and – if favorable – to perform a clinical trial of LA/C8 supplementation. Clinicians are encouraged to contact the authors before initiating LA/C8 supplementation in an affected individual to obtain current dosing recommendations and to allow for prospective collection of clinical data pre- and post-treatment.

#### **Revision History**

- 9 May 2019 (bp) Review posted live
- 12 June 2017 (gh) Original submission

# References

#### **Literature Cited**

- Heimer G, Kerätär JM, Riley LG, Balasubramaniam S, Eyal E, Pietikäinen LP, Hiltunen JK, Marek-Yagel D, Hamada J, Gregory A, Rogers C, Hogarth P, Nance MA, Shalva N, Veber A, Tzadok M, Nissenkorn A, Tonduti D, Renaldo F, Kraoua I, Panteghini C, Valletta L, Garavaglia B, Cowley MJ, Gayevskiy V, Roscioli T, Silberstein JM, Hoffmann C, Raas-Rothschild A, Tiranti V, Anikster Y, Christodoulou J, Kastaniotis AJ, Ben-Zeev B, Hayflick SJ, et al. MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder. Am J Hum Genet. 2016;99:1229–44. PubMed PMID: 27817865.
- Hiltunen JK, Schonauer MS, Autio KJ, Mittelmeier TM, Kastaniotis AJ, Dieckmann CL. Mitochondrial fatty acid synthesis type II: more than just fatty acids. J Biol Chem. 2009;284:9011–5. PubMed PMID: 19028688.
- Kursu VA, Pietikäinen LP, Fontanesi F, Aaltonen MJ, Suomi F, Raghavan Nair R, Schonauer MS, Dieckmann CL, Barrientos A, Hiltunen JK, Kastaniotis AJ. Defects in mitochondrial fatty acid synthesis result in failure of multiple aspects of mitochondrial biogenesis in Saccharomyces cerevisiae. Mol Microbiol. 2013;90:824–40. PubMed PMID: 24102902.
- Niezgoda J, Morgan PG. Anesthetic considerations in patients with mitochondrial defects. Paediatr Anaesth. 2013;23:785–93. PubMed PMID: 23534340.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24. PubMed PMID: 25741868.

# License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.